Teratogenicity of bromocryptine in pregnant rats

[1]  J. Siebers,et al.  Hemmung der Implantation bei der Ratte durch Bromocriptin , 2005, Archives of gynecology.

[2]  Kanofsky Jd,et al.  Prevention of thromboembolic disease by vitamin E. , 1981 .

[3]  M. Ferdeghini,et al.  Severe leukopenia and mild thrombocytopenia after chronic bromocriptine (CB-154) administration. , 1981, The American journal of the medical sciences.

[4]  J. Schenker,et al.  Conservative management of suspected prolactin secreting pituitary adenoma during pregnancy. , 1981, European journal of obstetrics, gynecology, and reproductive biology.

[5]  R. Manor,et al.  MYOPIA DURING BROMOCRIPTINE TREATMENT , 1981, The Lancet.

[6]  D. Calne,et al.  PLEUROPULMONARY CHANGES DURING LONG-TERM BROMOCRIPTINE TREATMENT FOR PARKINSON'S DISEASE , 1981, The Lancet.

[7]  K. Pearson.  Mental disorders from low-dose bromocriptine. , 1981, The New England journal of medicine.

[8]  Krauss Js.  Treatment of hemophilia with prothrombin-complex concentrates. , 1980 .

[9]  I. Blum,et al.  Increased hair loss as a side effect of bromocriptine treatment. , 1980, The New England journal of medicine.

[10]  Goodkin Da.  Mechanisms of bromocriptine-induced hallucinations. , 1980 .

[11]  S. Mendoza,et al.  Does high-dose ascorbic acid accelerate renal failure? , 1980, The New England journal of medicine.

[12]  D. Goodkin.  Mechanisms of bromocriptine-induced hallucinations. , 1980, The New England journal of medicine.

[13]  J. Siebers,et al.  [Inhibition of implantation in the rat due to bromocriptine (author's transl)]. , 1980, Archives of gynecology.

[14]  B. Reusens,et al.  Fetal plasma prolactin levels and fetal growth in relation to maternal CB-154 treatment in the rat. , 1979, General and comparative endocrinology.

[15]  C. Edwards,et al.  BROMOCRIPTINE-RESPONSIVE FORM OF IDIOPATHIC ŒDEMA , 1979, The Lancet.

[16]  G. Dickstein,et al.  New Drugs: Bromocriptine and Endocrine Disorders , 1979 .

[17]  I. Lancranjan,et al.  A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. , 1979, The Journal of clinical endocrinology and metabolism.

[18]  L. Wide,et al.  Clinical course and outcome of pregnancies in amenorrhoeic women with hyperprolactinaemia and pituitary tumours , 1978 .

[19]  R. Griffith,et al.  Outcome of pregnancy in mothers given bromocriptine. , 1978, British journal of clinical pharmacology.

[20]  R. Smithells.  Environmental teratogens of man. , 1977, British medical bulletin.

[21]  R. Smithells.  ENVIROMENTAL TERATOGENS OF MAN , 1976 .

[22]  G. Molinatti,et al.  Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine. , 1975, The Journal of clinical endocrinology and metabolism.

[23]  J. Grauwiler,et al.  Teratological experiments with ergotamine in mice, rats, and rabbits. , 1973, Teratology.

[24]  J. E. Robbers,et al.  Influence of ergot alkaloids on pituitary prolactin and prolactin-dependent processes. , 1973, Journal of pharmaceutical sciences.

[25]  G. Carpent,et al.  Effects of ergocornine on the mechanism of gestation and on fetal morphology in the rat. , 1969, Endocrinology.

[26]  J. Wilson.  Methods for administering agents and detecting malformations in experimental animals , 1965 .